Weiss Ratings Reaffirms Sell (E+) Rating for 908 Devices (NASDAQ:MASS)

Weiss Ratings reaffirmed their sell (e+) rating on shares of 908 Devices (NASDAQ:MASS) in a research note released on Friday,Weiss Ratings reports.

Other research analysts have also recently issued research reports about the stock. Leerink Partners reiterated a “market perform” rating and set a $4.00 price objective (down previously from $12.00) on shares of 908 Devices in a research report on Wednesday, November 13th. Stifel Nicolaus cut their price objective on shares of 908 Devices from $17.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Stephens reiterated an “overweight” rating and set a $6.00 price objective on shares of 908 Devices in a research report on Wednesday, January 15th. Finally, Leerink Partnrs cut shares of 908 Devices from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 13th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $5.33.

908 Devices Stock Performance

Shares of MASS opened at $2.76 on Friday. The company’s fifty day moving average is $2.51 and its 200 day moving average is $2.94. 908 Devices has a fifty-two week low of $1.81 and a fifty-two week high of $7.56. The stock has a market capitalization of $96.11 million, a PE ratio of -1.56 and a beta of 0.99.

Institutional Trading of 908 Devices

Large investors have recently made changes to their positions in the stock. Two Sigma Advisers LP purchased a new stake in shares of 908 Devices during the fourth quarter valued at $30,000. Prudential Financial Inc. purchased a new stake in shares of 908 Devices during the fourth quarter valued at $34,000. Occudo Quantitative Strategies LP purchased a new stake in shares of 908 Devices during the fourth quarter valued at $36,000. Two Sigma Investments LP purchased a new stake in shares of 908 Devices during the fourth quarter valued at $42,000. Finally, B. Riley Wealth Advisors Inc. purchased a new stake in shares of 908 Devices during the third quarter valued at $45,000. 88.06% of the stock is owned by hedge funds and other institutional investors.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.